Truelsen C G, Rønde H S, Kallehauge J F, Poulsen L Ø, Havelund B M, Pedersen B G, Iversen L H, Spindler K G, Kronborg C S
Danish Centre for Particle Therapy, Aarhus University Hospital, Denmark.
Department of Oncology, Aarhus University Hospital, Denmark.
Phys Imaging Radiat Oncol. 2024 Aug 23;31:100634. doi: 10.1016/j.phro.2024.100634. eCollection 2024 Jul.
Intensity modulated proton therapy (IMPT) enables generation of conformal dose plans with organ at risk (OAR) sparing potential. However, pelvic IMPT robustness is challenged by inter-fraction motion caused by constant anatomical variations. In this study, the dosimetric impact of inter-fraction motion on target coverage and dose to OAR was quantified in the prospective phase II study ReRad-II on dose-escalated proton reirradiation for locally recurrent rectal cancer (LRRC).
The inter-fraction motion robustness was assessed for the initial twelve patients enrolled in the ReRad-II study. Patients with resectable LRRC were assessed for neoadjuvant IMPT (55 Gy(RBE)/44Fx) and unresectable recurrences for definitive IMPT (57.5-65 Gy(RBE)/ 46-52Fx). Target coverage and dose to OAR were assessed for robustly optimised three-field IMPT, on 12 plan computerized tomography (CT) scans (pCT) - and 47 repetitive control CT scans (cCTs) during the treatment. The target coverage and doses to OAR were re-calculated on each cCT and the mean dose ratio (pCT/cCT-ratio) and target coverage (V) was evaluated.
The target coverage was robust with a mean dose pCT/cCT-ratio of 1.00 (+/-1%). The V target coverage for every cCT were above the accepted worst-case scenario in the robust evaluation. Considerable variation in bladder-, bowel bag-, and bowel loop volume was observed. The OAR with the largest variation in ratio was the bladder (pCT/cCT-ratio: 1.3 (range: 0.5-4.7).
IMPT for dose-escalated reirradiation of LRRC provided anatomically robust target coverage despite OAR changes. Inter-fraction motion resulted in OAR doses varying within clinically acceptable range.
调强质子治疗(IMPT)能够生成具有保护危及器官(OAR)潜力的适形剂量计划。然而,盆腔IMPT的稳健性受到持续解剖变异引起的分次间运动的挑战。在这项前瞻性II期研究ReRad-II中,对局部复发性直肠癌(LRRC)进行剂量递增质子再照射,量化了分次间运动对靶区覆盖和OAR剂量的剂量学影响。
对ReRad-II研究中最初入组的12例患者的分次间运动稳健性进行评估。可切除LRRC患者接受新辅助IMPT(55 Gy(RBE)/44次分割)评估,不可切除复发患者接受根治性IMPT(57.5 - 65 Gy(RBE)/46 - 52次分割)评估。在治疗期间,对12次计划计算机断层扫描(CT)扫描(pCT)和47次重复对照CT扫描(cCT)上稳健优化的三野IMPT评估靶区覆盖和OAR剂量。在每次cCT上重新计算靶区覆盖和OAR剂量,并评估平均剂量比(pCT/cCT比)和靶区覆盖(V)。
靶区覆盖稳健,平均剂量pCT/cCT比为1.00(±1%)。每次cCT的V靶区覆盖均高于稳健评估中可接受的最坏情况。观察到膀胱、肠袋和肠袢体积有相当大的变化。比值变化最大的OAR是膀胱(pCT/cCT比:1.3(范围:0.5 - 4.7))。
尽管OAR发生变化,但IMPT用于LRRC的剂量递增再照射仍能提供解剖学上稳健的靶区覆盖。分次间运动导致OAR剂量在临床可接受范围内变化。